Angiogenesis News and Research

RSS

Angiogenesis is blood vessel formation. Tumor angiogenesis is the growth of new blood vessels that tumors need to grow. This is caused by the release of chemicals by the tumor.

Compound developed as cholesterol-fighting molecule can kill cancerous cells

Researchers at the University of Missouri have proven that a compound initially developed as a cholesterol-fighting molecule not only halts the progression of breast cancer, but also can kill the cancerous cells.

18 Jun 2014

Bayer HealthCare seeks EU marketing authorization of EYLEA for macular edema following BRVO

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced that Bayer HealthCare has submitted an application to the European Medicines Agency (EMA) seeking marketing authorization in the European Union (EU) for EYLEA (aflibercept) Injection for the treatment of macular edema following branch retinal vein occlusion (BRVO).

11 Jun 2014

FCVB 2014 to feature cutting edge research in basic cardiovascular science

Cutting edge research in basic cardiovascular science will be presented at Frontiers in CardioVascular Biology (FCVB) 2014, held 4-6 July at the Palau de Congressos de Catalunya in Barcelona, Spain.

5 Jun 2014

Ovarian cancer patients with molecular subtypes benefit from bevacizumab

Molecular sequencing could identify ovarian cancer patients who are most likely to benefit from treatment with bevacizumab (Avastin), a Mayo Clinic-led study has found.

2 Jun 2014

Clovis Oncology reports lucitanib Phase 1/2a monotherapy study results at ASCO

Clovis Oncology today announced results from an ongoing Phase 1/2a monotherapy study evaluating lucitanib, the Company's novel, potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1 through 3 (FGFR1-3), vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFRα-β).

31 May 2014

Fibrogen reports FG-3019 Phase 2 study results for treatment of pancreatic cancer

FibroGen, Inc. today announced results from a Phase 2 open-label study of FG-3019, an investigational anti-fibrotic antibody, in combination with gemcitabine and erlotinib for the treatment of patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC).

31 May 2014

New data on Gilotrif and investigational compounds to be presented at 50th ASCO annual meeting

Boehringer Ingelheim today announced that new data will be presented from 7 abstracts for Gilotrif (afatinib) and investigational compounds, including nintedanib and BI 836845, from its oncology pipeline at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL, on May 30 – June 3, 2014.

31 May 2014

Eliminating scar tissue, inflammation may make tumors more deadly, find researchers

New research represents a significant change in the understanding of how pancreatic cancer grows - and how it might be defeated.

23 May 2014

Pro-urokinase promotes angiogenesis but does not reduce neuronal apoptosis in infarcted cerebral tissue

Among the drugs used for acute ischemic stroke, recombinant tissue plasminogen activator is widely accepted internationally. In China, urokinase has been widely used for thrombolysis after acute ischemic stroke.

13 May 2014

New drug approach for safer clean-up of deformed blood vessels in eye

A new drug approach has been developed for safer clean-up of deformed blood vessels in the eye by a research team at the Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital in Toronto.

12 May 2014

New research suggests that Kindlin-3 regulates 2 major hallmarks of breast cancer

A protein believed to be limited to the hematopoietic system, called Kindlin-3, has been identified as a major player in both the formation and spread of breast cancer to other organs.

2 May 2014

UT Southwestern docs receive grants for innovative studies on lung cancer pathways, drug therapy

Two UT Southwestern doctors have received more than a half-million dollars in grants from the Department of Defense for innovative studies on lung cancer pathways and to test the effectiveness of a potentially less expensive drug therapy.

2 May 2014

Biotech to the rescue

MIT professor Ram Sasisekharan's three biotech companies — Momenta Pharmaceuticals, Cerulean Pharma, and Visterra — share a similar goal.

1 May 2014

Adhesion molecule offers promising therapeutic target for preventing colitis

May Provide Therapeutic Target for Treating Inflammatory Bowel Disease and Preventing Colitis-Associated Colorectal Cancer, According to New Research Published in The American Journal of Pathology

29 Apr 2014

Promising new approach targets cancer protein to slow tumor growth

Sometimes a full-on assault isn't the best approach when dealing with a powerful enemy. A more effective approach, in the long run, may be to target the support system replenishing the supplies that keep your foe strong and ready for battle.

26 Apr 2014

FDA approves Cyramza to treat patients with advanced stomach cancer

Based on results of a clinical trial led by Dana-Farber Cancer Institute scientists, the U.S. Food and Drug Administration (FDA) approved a molecularly targeted drug as second-line treatment in advanced stomach cancer that has progressed after standard chemotherapy has failed.

22 Apr 2014

FDA approves molecularly targeted drug as second-line treatment for advanced stomach cancer

Based on results of a clinical trial led by Dana-Farber Cancer Institute scientists, the U.S. Food and Drug Administration approved a molecularly targeted drug as second-line treatment in advanced stomach cancer that has progressed after standard chemotherapy has failed.

22 Apr 2014

FDA and EC grant Orphan Drug Designation to Boehringer’s volasertib for acute myeloid leukemia

Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) and European Commission (EC) have granted Orphan Drug Designation to volasertib for acute myeloid leukemia (AML).

21 Apr 2014

Iconic Therapeutics completes $20 million Series B-1 equity financing

Iconic Therapeutics, Inc., a biotechnology company focused on developing therapeutics for serious eye disorders, announced today that it has successfully completed a $20 million Series B-1 equity financing from new investors MPM Capital, Lundbeckfond Ventures, and H.I.G. BioVentures.

16 Apr 2014

BioLineRx to initiate Phase 1/2 clinical trial on new drug candidate for CML treatment

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that Prof. Arnon Nagler, Director of the Hematology Division and Bone Marrow Transplantation Center at Sheba Medical Center, Israel, has received final regulatory approval to evaluate BioLineRx's BL-8040 as a treatment for chronic myeloid leukemia (CML) in a Phase 1/2 clinical study.

10 Apr 2014

Angiogenesis News and Research

Further Reading

Compound developed as cholesterol-fighting molecule can kill cancerous cells

Bayer HealthCare seeks EU marketing authorization of EYLEA for macular edema following BRVO

FCVB 2014 to feature cutting edge research in basic cardiovascular science

Ovarian cancer patients with molecular subtypes benefit from bevacizumab

Clovis Oncology reports lucitanib Phase 1/2a monotherapy study results at ASCO

Fibrogen reports FG-3019 Phase 2 study results for treatment of pancreatic cancer

New data on Gilotrif and investigational compounds to be presented at 50th ASCO annual meeting

Eliminating scar tissue, inflammation may make tumors more deadly, find researchers

Pro-urokinase promotes angiogenesis but does not reduce neuronal apoptosis in infarcted cerebral tissue

New drug approach for safer clean-up of deformed blood vessels in eye

New research suggests that Kindlin-3 regulates 2 major hallmarks of breast cancer

UT Southwestern docs receive grants for innovative studies on lung cancer pathways, drug therapy

Biotech to the rescue

Adhesion molecule offers promising therapeutic target for preventing colitis

Promising new approach targets cancer protein to slow tumor growth

FDA approves Cyramza to treat patients with advanced stomach cancer

FDA approves molecularly targeted drug as second-line treatment for advanced stomach cancer

FDA and EC grant Orphan Drug Designation to Boehringer’s volasertib for acute myeloid leukemia

Iconic Therapeutics completes $20 million Series B-1 equity financing

BioLineRx to initiate Phase 1/2 clinical trial on new drug candidate for CML treatment

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo